Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURGA-5 in transplant-ineligible newly diagnosed multiple myeloma
jRCT2053260153Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3, randomised, open-label trial of GC012 in multiple myeloma (MM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and MRD-negative complete response rate at 9 months. Started Oct 2026; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2053260153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053260153.